Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582083 | 0.82 | NR3C2 (0.49) | PDK2PDK1PDK3PDK4NR3C1 | |
| SCHEMBL6583330 | 0.79 | MAOB (0.40) | MLYCDEPHX2NR3C1PGRNR3C2 | |
| SCHEMBL6585240 | 0.78 | EPHX2 (0.40) | MLYCDEPHX2NR3C1PGRNR3C2 | |
| SCHEMBL6554688 | 0.77 | NR3C1 (0.51) | PDK2PDK1PDK3PDK4NR3C1 | |
| SCHEMBL6583893 | 0.77 | TET2 (0.38) | NR3C1PGRNR3C2NR1H3NR1H2 | |
| SCHEMBL28846139 | 0.75 | KIF11 (0.48) | MLYCDPDK2PDK1PDK3PDK4 | |
| SCHEMBL6583154 | 0.74 | NR3C1 (0.36) | PDK2PDK1PDK3PDK4NR3C1 | |
| SCHEMBL6245761 | 0.73 | KIF11 (0.50) | MLYCDPDK2PDK1PDK3PDK4 | |
| SCHEMBL22939513 | 0.72 | SHBG (0.55) | EPHX2KIF11 | |
| SCHEMBL8224210 | 0.71 | KIF11 (0.52) | EPHX2PTPN5KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | claimed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | claimed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | claimed |
| CN-100445272-C | Non-steroidal (hetero) cyclically substd. acylanilides with mixed gestagen and androgen activity | SCHERING AG (DE) | 2008-12-24 | — | — | CN | disclosed |
| EP-0986545-B1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6548534-B2 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| CN-1258286-A | Non-steroidal (hetero) cyclically substd. acylanilides with mixed gestagen and androgen activity | SCHERING AG (DE) | 2000-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | MLYCD 4266/4885PDK2 1868/4885PDK1 2157/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | MLYCD 4231/4885PDK2 1961/4885PDK1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.